117 related articles for article (PubMed ID: 27791987)
1. Jie-du granule preparation for the treatment of advanced hepatocellular carcinoma: a retrospective cohort study of 177 patients.
Chen LY; Zhai XF; Chen Z; Zhu JF; Qian PA; Zhao HT; Ling CQ
Oncotarget; 2017 May; 8(18):30471-30476. PubMed ID: 27791987
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
[TBL] [Abstract][Full Text] [Related]
4. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study.
Zhao HT; Meng YB; Zhai XF; Cheng BB; Yu SS; Yao M; Yin HX; Wan XY; Yang YK; Liu H; Shen F; Ling CQ
J Integr Med; 2020 Jul; 18(4):319-325. PubMed ID: 32532615
[TBL] [Abstract][Full Text] [Related]
5. A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China.
Sun L; Fahey P; Zhu X; Ng W; Chen ZP; Qiu Y; Lai H; Lin J; Lin L
Integr Cancer Ther; 2018 Sep; 17(3):902-911. PubMed ID: 29775121
[TBL] [Abstract][Full Text] [Related]
6. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.
Liu X; Li M; Wang X; Dang Z; Yu L; Wang X; Jiang Y; Yang Z
Phytomedicine; 2019 Sep; 62():152930. PubMed ID: 31128485
[TBL] [Abstract][Full Text] [Related]
7. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.
Yu Y; Lang Q; Chen Z; Li B; Yu C; Zhu D; Zhai X; Ling C
Cancer; 2009 Nov; 115(22):5132-8. PubMed ID: 19672999
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
Adhoute X; Pénaranda G; Raoul JL; Blanc JF; Edeline J; Conroy G; Perrier H; Pol B; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):433-40. PubMed ID: 26695429
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
10. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
12. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
16. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Sinn DH; Cho JY; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
PLoS One; 2015; 10(4):e0124434. PubMed ID: 25923439
[TBL] [Abstract][Full Text] [Related]
17. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
19. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
